Revolutionary vaccines to prevent pandemic and seasonal outbreaks of respiratory viral infections: The best-in-class UNIVERSAL multi-season influenza vaccine

Project Information

OSIRIX

Grant agreement ID: 961112

DOI 10.3030/961112

Project closed

EC signature date 16 July 2020

Start date 1 April 2020

End date 30 September 2022

Funded under

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Total cost € 3 515 889,25

EU contribution € 2 461 122,48

Coordinated by

OSIVAX SAS
France